Arnd Nusch

6.2k total citations · 1 hit paper
50 papers, 729 citations indexed

About

Arnd Nusch is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Arnd Nusch has authored 50 papers receiving a total of 729 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pulmonary and Respiratory Medicine, 24 papers in Oncology and 18 papers in Cancer Research. Recurrent topics in Arnd Nusch's work include Advanced Breast Cancer Therapies (27 papers), Cancer Treatment and Pharmacology (11 papers) and Breast Cancer Treatment Studies (11 papers). Arnd Nusch is often cited by papers focused on Advanced Breast Cancer Therapies (27 papers), Cancer Treatment and Pharmacology (11 papers) and Breast Cancer Treatment Studies (11 papers). Arnd Nusch collaborates with scholars based in Germany, United States and Switzerland. Arnd Nusch's co-authors include Norbert Marschner, Patrick Neven, Guy Jérusalem, J. Thaddeus Beck, Giulia Bianchi, Luis de la Cruz‐Merino, Michelino De Laurentiis, Gabe S. Sonke, Katarína Petráková and Martina Jänicke and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Arnd Nusch

46 papers receiving 718 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

2021 161 citations Dennis J. Slamon, Patrick Neven et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Arnd Nusch Germany	14	476	437	215	132	126	50	729
Katarzyna Pogoda Poland	11	392 0.8×	512 1.2×	176 0.8×	118 0.9×	89 0.7×	53	721
Roel J.W. van Kampen Netherlands	13	283 0.6×	562 1.3×	261 1.2×	100 0.8×	118 0.9×	18	891
Sarah Sammons United States	16	399 0.8×	466 1.1×	168 0.8×	97 0.7×	119 0.9×	92	706
R. Corre France	17	816 1.7×	541 1.2×	113 0.5×	149 1.1×	84 0.7×	88	1.0k
Céline Ferlay France	15	460 1.0×	259 0.6×	183 0.9×	139 1.1×	285 2.3×	37	776
Claudia Andreetta Italy	16	205 0.4×	517 1.2×	296 1.4×	49 0.4×	162 1.3×	41	831
Melissa Brammer United States	12	351 0.7×	585 1.3×	148 0.7×	78 0.6×	81 0.6×	36	747
Janice F. Eakle United States	9	345 0.7×	565 1.3×	265 1.2×	58 0.4×	246 2.0×	22	805
Sonia Yip Australia	14	361 0.8×	308 0.7×	83 0.4×	56 0.4×	84 0.7×	75	662
Ewa Matczak United States	13	384 0.8×	295 0.7×	147 0.7×	180 1.4×	282 2.2×	24	866

Countries citing papers authored by Arnd Nusch

Since Specialization

Citations

This map shows the geographic impact of Arnd Nusch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arnd Nusch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arnd Nusch more than expected).

Fields of papers citing papers by Arnd Nusch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arnd Nusch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arnd Nusch. The network helps show where Arnd Nusch may publish in the future.

Co-authorship network of co-authors of Arnd Nusch

This figure shows the co-authorship network connecting the top 25 collaborators of Arnd Nusch. A scholar is included among the top collaborators of Arnd Nusch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arnd Nusch. Arnd Nusch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thill, Marc, Anja Welt, Arnd Nusch, et al.. (2024). Head‐to‐head comparison of palbociclib and ribociclib in first‐line treatment of HR‐positive/HER2‐negative metastatic breast cancer with real‐world data from the OPAL registry. International Journal of Cancer. 156(9). 1770–1782. 5 indexed citations

Untch, Michael, David Pérol, Erica L. Mayer, et al.. (2024). Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis. European Journal of Cancer. 202. 113977–113977. 7 indexed citations

Neven, Patrick, PA Fasching, Stephen Chia, et al.. (2023). Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Research. 25(1). 103–103. 33 indexed citations

Decker, Thomas, Cosima Brucker, Peter A. Fasching, et al.. (2023). 409P Treatment of elderly patients (pts; > 75 years) with 1st-line ribociclib (RIB) + endocrine therapy (ET) or endocrine monotherapy in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA)). Annals of Oncology. 34. S354–S355. 2 indexed citations

Fasching, Peter A., Cosima Brucker, Thomas Decker, et al.. (2023). Abstract P4-01-03: Progression-free survival and patient-reported outcomes in HR+, HER2– ABC patients treated with first-line ribociclib + endocrine therapy (ET) or ET monotherapy or chemotherapy in real world setting: 5th interim analysis of RIBANNA. Cancer Research. 83(5_Supplement). P4–1. 2 indexed citations

Marschner, Norbert, Nadia Harbeck, Elmar Stickeler, et al.. (2022). 232P Second-line therapies of patients with early progression under CDK4/6-inhibitor in first-line – data from the registry platform OPAL. Annals of Oncology. 33. S643–S644. 3 indexed citations

Jakob, Andreas, Arnd Nusch, Roland Schnell, et al.. (2022). Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study. Journal of bone oncology. 33. 100420–100420. 7 indexed citations

Fasching, Peter A., Aditya Bardia, Arnd Nusch, et al.. (2021). 91O Pooled analysis of patient (pt)-reported outcomes (PROs) in the MONALEESA (ML)-2, -3, and -7 trials: Additional results and key subgroup findings. Annals of Oncology. 32. S60–S61. 1 indexed citations

Slamon, Dennis J., Patrick Neven, Stephen Chia, et al.. (2021). Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Annals of Oncology. 32(8). 1015–1024. 161 indexed citations breakdown →

10.

Jérusalem, Guy, Thomas E. Delea, Michelino De Laurentiis, et al.. (2021). Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial. Clinical Breast Cancer. 22(4). 326–335. 4 indexed citations

11.

Fasching, Peter A., J. Thaddeus Beck, Arlene Chan, et al.. (2020). Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. The Breast. 54. 148–154. 27 indexed citations

12.

Jérusalem, Guy, Thomas E. Delea, M. Martín Jiménez, et al.. (2020). 142P Quality-adjusted survival with ribociclib plus fulvestrant (R+F) versus placebo plus fulvestrant (P+F) in postmenopausal women (PMW) HR+/HER2- advanced breast cancer (ABC) based on the MONALEESA-3 trial. Annals of Oncology. 31. S66–S66. 2 indexed citations

13.

Welt, Anja, Marc Thill, Elmar Stickeler, et al.. (2020). 324P What affects the choice of first-line treatment for hormone-receptor-positive, HER2-negative advanced breast cancer? Data from the German research platform OPAL. Annals of Oncology. 31. S373–S374. 2 indexed citations

14.

Marschner, Norbert, Christoph Salat, Ulrike Söling, et al.. (2018). Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab-Paclitaxel. Clinical Breast Cancer. 18(6). e1323–e1337. 12 indexed citations

15.

Goebell, Peter J., Michael Staehler, Lothar Müller, et al.. (2018). Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma – Analyses From the German Clinical RCC-Registry. Clinical Genitourinary Cancer. 16(6). e1101–e1115. 21 indexed citations

16.

Decker, Thomas, Friedrich Overkamp, Siegfried Rösel, et al.. (2017). A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO). BMC Cancer. 17(1). 499–499. 22 indexed citations

17.

Marschner, Norbert, Michael Staehler, Lothar Müller, et al.. (2016). Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials—Analyses From the German Clinical RCC Registry. Clinical Genitourinary Cancer. 15(2). e209–e215. 44 indexed citations

18.

Schmidt, Christian, Sebastian Fetscher, Christian Görg, et al.. (2011). Treatment of Indolent Lymphoma in Germany - Results of a Representative Population-Based Survey. Clinical Lymphoma Myeloma & Leukemia. 11(2). 204–211. 10 indexed citations

19.

Huober, Jens, W. Fett, Arnd Nusch, et al.. (2010). A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer. BMC Cancer. 10(1). 2–2. 40 indexed citations

20.

Graeven, Ullrich, Dirk Arnold, Anke Reinacher‐Schick, et al.. (2007). A Randomised Phase II Study of Irinotecan in Combination with 5-FU/FA Compared with Irinotecan Alone as Second-Line Treatment of Patients with Metastatic Colorectal Carcinoma. Oncology Research and Treatment. 30(4). 169–174. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact